Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

The use of radiopharmaceutical therapies (RPTs) in the treatment of cancers is growing
rapidly, with more agents becoming available for clinical use in last few years and many new …

Background Treatment options for metastatic castration-resistant prostate cancer (mCRPC)
have expanded in recent years and include cytotoxic agents (eg, docetaxel and …

CT and bone scintigraphy are not useful for response evaluation of bone metastases to
223Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). PET using …

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer
(mCRPC) remains challenging due to alternative options and short window of opportunity …

Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that
shows an improvement in overall survival (OS) in metastatic castrate resistant prostate …

Over the years, an increasing proportion of metastatic prostate cancer patients has been
found to experience an initial bone flare phenomenon under both standard therapies …

Simple Summary Radium-223 dichloride ([223Ra] RaCl2; Ra-223) is an alpha-emitting
radiopharmaceutical treatment for patients with metastatic castration resistant prostate …

Whole-body MR Imaging (WB-MR Imaging) is increasingly recommended as a radiation-free
imaging method for detecting bone and soft tissue pathology, and for evaluating response to …

Abstract Radium-223 dichloride (radium-223) was approved for the treatment of patients
with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the …